gsk boston pharmaceuticals

News

GSK buys liver drug from Boston Pharmaceuticals

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their exclusivity periods.

· 4h · on MSN

PharmExec · 17h

GSK Acquires Boston Pharmaceuticals’ Novel FGF21 Analog for Steatotic Liver Disease

· 19h · on MSN

GSK to buy liver disease drug for up to $2 billion

Pharmabiz5h

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...

STAT20h

GSK to buy experimental MASH drug for $1.2B upfront

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

GSK buys liver drug from Boston Pharmaceuticals

Trending now